CORRESP Filing
Annovis Bio, Inc.
Date: Sept. 29, 2025 · CIK: 0001477845 · Accession: 0001104659-25-094016
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39202
Referenced dates: September 4, 2025
Letter
Via EDGAR September 19, 2025 Ms. Jenn Do and Ms. Vanessa Robertson U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549
Re: Annovis Bio, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed March 21, 2025 File No. 001-39202
Dear Ms. Do and Ms. Robertson:
Annovis Bio, Inc. (the "Company") is in receipt of the Staff's letter dated September 4, 2025 (the "Staff's Letter") regarding the Company's Annual Report on Form 10-K (the "Form 10-K"). In the letter the Staff requested that the Company provide a breakdown of the Alzheimer's and Parkinson's studies. Our 2024 10-K states that the company "tracks and records information regarding external research and development expenses for each study or trial that we conduct." This is an inaccurate statement as it pertains to the breakout of Alzheimer's and Parkinson's studies and was meant to say that we are tracking clinical as well as manufacturing, pre-clinical, and research expenses.
The Company hereby agrees that, beginning with the 3rd quarter of 2025, we will track Alzheimer 's and Parkinson's expenses separately. We will provide narrative disclosure on a going-forward basis only (no prior period comparison) regarding the breakdown of research and development expenses between the Alzheimer's study and the Parkinson's study. In addition, the filings will continue to show the breakdown as reported in previous filings, Exhibit A. We will provide comparative analysis of the clinical study expenses when the information becomes available.
Please contact me at (610) 880-8485 or by email at maccecchini@annovisbio.com if you have any additional questions.
Sincerely,
Maria Maccecchini
Show Raw Text
CORRESP 1 filename1.htm Via EDGAR September 19, 2025 Ms. Jenn Do and Ms. Vanessa Robertson U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Re: Annovis Bio, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed March 21, 2025 File No. 001-39202 Dear Ms. Do and Ms. Robertson: Annovis Bio, Inc. (the "Company") is in receipt of the Staff's letter dated September 4, 2025 (the "Staff's Letter") regarding the Company's Annual Report on Form 10-K (the "Form 10-K"). In the letter the Staff requested that the Company provide a breakdown of the Alzheimer's and Parkinson's studies. Our 2024 10-K states that the company "tracks and records information regarding external research and development expenses for each study or trial that we conduct." This is an inaccurate statement as it pertains to the breakout of Alzheimer's and Parkinson's studies and was meant to say that we are tracking clinical as well as manufacturing, pre-clinical, and research expenses. The Company hereby agrees that, beginning with the 3rd quarter of 2025, we will track Alzheimer 's and Parkinson's expenses separately. We will provide narrative disclosure on a going-forward basis only (no prior period comparison) regarding the breakdown of research and development expenses between the Alzheimer's study and the Parkinson's study. In addition, the filings will continue to show the breakdown as reported in previous filings, Exhibit A. We will provide comparative analysis of the clinical study expenses when the information becomes available. Please contact me at (610) 880-8485 or by email at maccecchini@annovisbio.com if you have any additional questions. Sincerely, Maria Maccecchini President and Chief Executive Officer EXHIBIT A R&D Expenses for the quarters ended 1/1/2024 - 12/31/2024 1/1/2024- 3/31/2025 4/1/2025- 6/30/2025 1/1/2025- 6/30/2025 Clinical (AD & PD) 16,238,273 4,072,968 4,249,437 8,322,405 CMC 2,589,833 713,132 681,885 1,395,017 Preclinical 1,167,341 225,416 230,600 456,016 19,995,447 5,011,517 5,161,921 10,173,438 2